Cargando…
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898594/ https://www.ncbi.nlm.nih.gov/pubmed/35914224 http://dx.doi.org/10.1182/bloodadvances.2022007538 |
| _version_ | 1784882458752188416 |
|---|---|
| author | Rindone, Giovanni Aroldi, Andrea Bossi, Elisa Verga, Luisa Zambrotta, Giovanni Tarantino, Sara Piazza, Rocco Mussolin, Lara Chiarle, Roberto Gambacorti-Passerini, Carlo |
| author_facet | Rindone, Giovanni Aroldi, Andrea Bossi, Elisa Verga, Luisa Zambrotta, Giovanni Tarantino, Sara Piazza, Rocco Mussolin, Lara Chiarle, Roberto Gambacorti-Passerini, Carlo |
| author_sort | Rindone, Giovanni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9898594 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98985942023-02-09 A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas Rindone, Giovanni Aroldi, Andrea Bossi, Elisa Verga, Luisa Zambrotta, Giovanni Tarantino, Sara Piazza, Rocco Mussolin, Lara Chiarle, Roberto Gambacorti-Passerini, Carlo Blood Adv Research Letter The American Society of Hematology 2022-08-03 /pmc/articles/PMC9898594/ /pubmed/35914224 http://dx.doi.org/10.1182/bloodadvances.2022007538 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Research Letter Rindone, Giovanni Aroldi, Andrea Bossi, Elisa Verga, Luisa Zambrotta, Giovanni Tarantino, Sara Piazza, Rocco Mussolin, Lara Chiarle, Roberto Gambacorti-Passerini, Carlo A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title | A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title_full | A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title_fullStr | A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title_full_unstemmed | A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title_short | A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas |
| title_sort | monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory alk(+) lymphomas |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898594/ https://www.ncbi.nlm.nih.gov/pubmed/35914224 http://dx.doi.org/10.1182/bloodadvances.2022007538 |
| work_keys_str_mv | AT rindonegiovanni amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT aroldiandrea amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT bossielisa amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT vergaluisa amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT zambrottagiovanni amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT tarantinosara amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT piazzarocco amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT mussolinlara amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT chiarleroberto amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT gambacortipasserinicarlo amonocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT rindonegiovanni monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT aroldiandrea monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT bossielisa monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT vergaluisa monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT zambrottagiovanni monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT tarantinosara monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT piazzarocco monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT mussolinlara monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT chiarleroberto monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas AT gambacortipasserinicarlo monocentricanalysisofthelongtermsafetyandefficacyofcrizotinibinrelapsedrefractoryalklymphomas |